Plant-based Gaucher's drug passes Phase III trial
This article was originally published in Scrip
Executive Summary
Protalix Biotherapeutics' lead-drug candidate, Uplyso (taliglucerase alfa; formerly prGCD), was safe and effective in its pivotal Phase III trial, show top-line results. With these results, the company's Gaucher's disease therapy inches closer to becoming the first transgenicplant-produced drug to be approved for human use.